Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 2/20 | 0.42 |
| ▸ | LCAT | P04180 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117672 | 0.87 | GRIN2B (0.51) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19998597 | 0.84 | GPR119 (0.49) | USP30PDE10AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL29455716 | 0.83 | MAPT (0.47) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7956825 | 0.78 | AKR1C3 (0.54) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15206004 | 0.78 | AKR1C3 (0.52) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22117621 | 0.78 | PDE10A (0.41) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18124185 | 0.77 | AVPR1A (0.54) | — | |
| SCHEMBL5236585 | 0.77 | AKR1C3 (0.61) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14127792 | 0.76 | GRIN2D (0.49) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14127793 | 0.76 | MAPT (0.57) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| EP-2479165-A1 | GLYCINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-2479165-A1 | GLYCINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| CN-102498091-A | Glycine compound | ASTELLAS PHARMA INC | 2012-06-13 | — | — | CN | disclosed |
| WO-2011034078-A1 | GLYCINE COMPOUND | アステラス製薬株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184520-A1 | GLYCINE COMPOUND | SLC5A1, AQP1, VAPB | USP30 4182/4885PDE10A 3606/4885GRIN2D 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.